The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
DARZALEX SC Janssen-Cilag Pty Ltd
Product name
DARZALEX SC
Sponsor
Accepted date
Jan-2025
Active ingredients
daratumumab
Proposed indication
DARZALEX SC is for the treatment of patients with newly-diagnosed multiple myeloma (a type of cancer that affects antibody-secreting cells) who are ineligible for a stem cell transplant. It is also used to treat high-risk smouldering multiple myeloma (a slow-growing version of multiple myeloma)
Application type
C (new indication)
Publication date
Jan-2025